Consistent with the above results, KDM5B knockdown reduced tumorigenesis in vivo, showing that BXPC-3 cells with KDM5B knockdown displayed reduced tumor growth rate, size and Ki67, CD133 positive cells, compared to the control group, respectively (Fig. 2G–I, M). This evidence concerns the gene KDM5B and neoplasm.